Amgen posts higher-than-expected third quarter results, but shares dip

1

By Deena Beasley Nov 3 (Reuters) – Amgen on Tuesday said third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy Uplizna, as

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)